|
Shire completes sale of oncology franchise
|
31 August 2018 |
|
PatientsLikeMe and Shire Pharmaceuticals collaborate to study rare genetic diseases
|
12 April 2017 |
|
Shire to establish rare disease innovation hub in Cambridge, Mass.
|
23 November 2016 |
|
Vonvendi, the first and only recombinant treatment for adults affected by von Willebrand disease, launches in the USA
|
09 August 2016 |
|
One family's history of the rare condition Fabry disease through the generations
|
28 April 2016 |
|
Shire to combine with Baxalta, creating the global leader in rare diseases
|
14 January 2016 |
|
Shire partners with CrowdMed to offer US employees an innovative digital crowdsourcing diagnostic service
|
09 December 2015 |
|
Shire acquires Meritage Pharma
|
24 February 2015 |
|
Shire acquires Premacure AB
|
12 March 2013 |
|
Shire and Boston Children's Hospital enter into broad research collaboration
|
20 November 2012 |
|
Shire continued strong product sales performance in Q3
|
28 October 2011 |
|
Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc.
|
18 May 2011 |
|
Shire delivers a strong first quarter performance
|
28 April 2011 |
|
Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse®
|
10 January 2011 |
|
Shire Expands Pipeline to Treat Orphan Muscle Diseases through Collaboration with Acceleron Pharma
|
10 September 2010 |
|
Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships
|
01 September 2010 |
|
Shire Proposes to Expand Specialist Gastrointestinal Portfolio
|
04 August 2010 |
|
Shire Purchases Strategic Site in Massachusetts
|
01 July 2010 |
|
VYVANSE® - new ADHD treatment option - now available in Canada
|
02 February 2010 |
|
FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity
|
26 October 2009 |